# Applied Materials Inc: financial statements, quarterly AMAT · Nasdaq · CIK 6951 · [Technology](/sectors/technology.md) · fiscal year ends Oct 26 Pages: [Overview](/companies/amat.md) · [Financials](/companies/amat/financials.md) · [Filings](/companies/amat/filings.md) · [Insiders](/companies/amat/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/amat/financials.md?period=annual). ## Income statement | Line item | Unit | Q4 FY2023 (2023-10-29) | Q1 FY2024 (2024-01-28) | Q2 FY2024 (2024-04-28) | Q3 FY2024 (2024-07-28) | Q4 FY2024 (2024-10-27) | Q1 FY2025 (2025-01-26) | Q2 FY2025 (2025-04-27) | Q3 FY2025 (2025-07-27) | Q4 FY2025 (2025-10-26) | Q1 FY2026 (2026-01-25) | Q2 FY2026 (2026-04-26) | Q3 FY2026 (2026-07-26) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [6,723 d](/filings/0001628280-25-056742.md) | [6,707](/filings/0000006951-25-000011.md) | [6,646](/filings/0000006951-25-000024.md) | [6,778](/filings/0000006951-25-000037.md) | [7,045 d](/filings/0001628280-25-056742.md) | [7,166](/filings/0001628280-26-009694.md) | [7,100](/filings/0001628280-26-037227.md) | [7,302](/filings/0001628280-26-058235.md) | [6,800 d](/filings/0001628280-25-056742.md) | [7,012](/filings/0001628280-26-009694.md) | [7,910](/filings/0001628280-26-037227.md) | [9,115](/filings/0001628280-26-058235.md) | | Cost of revenue | $m | [3,554 d](/filings/0001628280-25-056742.md) | [3,503](/filings/0000006951-25-000011.md) | [3,493](/filings/0000006951-25-000024.md) | [3,573](/filings/0000006951-25-000037.md) | [3,710 d](/filings/0001628280-25-056742.md) | [3,670](/filings/0001628280-26-009694.md) | [3,615](/filings/0001628280-26-037227.md) | [3,740](/filings/0001628280-26-058235.md) | [3,535 d](/filings/0001628280-25-056742.md) | [3,577](/filings/0001628280-26-009694.md) | [3,963](/filings/0001628280-26-037227.md) | [4,529](/filings/0001628280-26-058235.md) | | Gross profit | $m | [3,169 d](/filings/0001628280-25-056742.md) | [3,204](/filings/0000006951-25-000011.md) | [3,153](/filings/0000006951-25-000024.md) | [3,205](/filings/0000006951-25-000037.md) | [3,335 d](/filings/0001628280-25-056742.md) | [3,496](/filings/0001628280-26-009694.md) | [3,485](/filings/0001628280-26-037227.md) | [3,562](/filings/0001628280-26-058235.md) | [3,265 d](/filings/0001628280-25-056742.md) | [3,435](/filings/0001628280-26-009694.md) | [3,947](/filings/0001628280-26-037227.md) | [4,586](/filings/0001628280-26-058235.md) | | Research and development | $m | [789 d](/filings/0001628280-25-056742.md) | [754](/filings/0000006951-25-000011.md) | [785](/filings/0000006951-25-000024.md) | [836](/filings/0000006951-25-000037.md) | [858 d](/filings/0001628280-25-056742.md) | [859](/filings/0001628280-26-009694.md) | [893](/filings/0001628280-26-037227.md) | [901](/filings/0001628280-26-058235.md) | [917 d](/filings/0001628280-25-056742.md) | [928](/filings/0001628280-26-009694.md) | [1,027](/filings/0001628280-26-037227.md) | [1,100](/filings/0001628280-26-058235.md) | | Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | [462](/filings/0001628280-26-009694.md) | [423](/filings/0001628280-26-037227.md) | [428](/filings/0001628280-26-058235.md) | [455 d](/filings/0001628280-25-056742.md) | [411](/filings/0001628280-26-009694.md) | [397](/filings/0001628280-26-037227.md) | [411](/filings/0001628280-26-058235.md) | | Operating income | $m | [1,971 d](/filings/0001628280-25-056742.md) | [1,967](/filings/0000006951-25-000011.md) | [1,912](/filings/0000006951-25-000024.md) | [1,942](/filings/0000006951-25-000037.md) | [2,046 d](/filings/0001628280-25-056742.md) | [2,175](/filings/0001628280-26-009694.md) | [2,169](/filings/0001628280-26-037227.md) | [2,233](/filings/0001628280-26-058235.md) | [1,712 d](/filings/0001628280-25-056742.md) | [1,831](/filings/0001628280-26-009694.md) | [2,523](/filings/0001628280-26-037227.md) | [3,075](/filings/0001628280-26-058235.md) | | Interest expense | $m | [58.0 d](/filings/0000006951-23-000041.md) | [59.0](/filings/0000006951-24-000012.md) | [59.0](/filings/0000006951-24-000022.md) | [63.0](/filings/0000006951-25-000037.md) | [66.0 d](/filings/0001628280-25-056742.md) | [64.0](/filings/0001628280-26-009694.md) | [68.0](/filings/0001628280-26-037227.md) | [66.0](/filings/0001628280-26-058235.md) | [71.0 d](/filings/0001628280-25-056742.md) | [69.0](/filings/0001628280-26-009694.md) | [69.0](/filings/0001628280-26-037227.md) | [68.0](/filings/0001628280-26-058235.md) | | Income tax | $m | [168 d](/filings/0001628280-25-056742.md) | [284](/filings/0000006951-25-000011.md) | [272](/filings/0000006951-25-000024.md) | [255](/filings/0000006951-25-000037.md) | [164 d](/filings/0001628280-25-056742.md) | [934](/filings/0001628280-26-009694.md) | [185](/filings/0001628280-26-037227.md) | [784](/filings/0001628280-26-058235.md) | [370 d](/filings/0001628280-25-056742.md) | [302](/filings/0001628280-26-009694.md) | [419](/filings/0001628280-26-037227.md) | [369](/filings/0001628280-26-058235.md) | | Net income | $m | [2,004 d](/filings/0001628280-25-056742.md) | [2,019](/filings/0000006951-25-000011.md) | [1,722](/filings/0000006951-25-000024.md) | [1,705](/filings/0000006951-25-000037.md) | [1,731 d](/filings/0001628280-25-056742.md) | [1,185](/filings/0001628280-26-009694.md) | [2,137](/filings/0001628280-26-037227.md) | [1,779](/filings/0001628280-26-058235.md) | [1,897 d](/filings/0001628280-25-056742.md) | [2,026](/filings/0001628280-26-009694.md) | [2,806](/filings/0001628280-26-037227.md) | [2,538](/filings/0001628280-26-058235.md) | | Diluted EPS | $ per share | not reported | [2.41](/filings/0000006951-25-000011.md) | [2.06](/filings/0000006951-25-000024.md) | [2.05](/filings/0000006951-25-000037.md) | not reported | [1.45](/filings/0001628280-26-009694.md) | [2.63](/filings/0001628280-26-037227.md) | [2.22](/filings/0001628280-26-058235.md) | not reported | [2.54](/filings/0001628280-26-009694.md) | [3.51](/filings/0001628280-26-037227.md) | [3.17](/filings/0001628280-26-058235.md) | | Basic EPS | $ per share | not reported | [2.43](/filings/0000006951-25-000011.md) | [2.08](/filings/0000006951-25-000024.md) | [2.06](/filings/0000006951-25-000037.md) | not reported | [1.46](/filings/0001628280-26-009694.md) | [2.64](/filings/0001628280-26-037227.md) | [2.23](/filings/0001628280-26-058235.md) | not reported | [2.55](/filings/0001628280-26-009694.md) | [3.53](/filings/0001628280-26-037227.md) | [3.20](/filings/0001628280-26-058235.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-10-29) | Q1 FY2024 (2024-01-28) | Q2 FY2024 (2024-04-28) | Q3 FY2024 (2024-07-28) | FY2024 (2024-10-27) | Q1 FY2025 (2025-01-26) | Q2 FY2025 (2025-04-27) | Q3 FY2025 (2025-07-27) | FY2025 (2025-10-26) | Q1 FY2026 (2026-01-25) | Q2 FY2026 (2026-04-26) | Q3 FY2026 (2026-07-26) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $bn | [6.1](/filings/0001628280-25-056742.md) | [6.9](/filings/0000006951-25-000011.md) | [7.1](/filings/0000006951-25-000024.md) | [8.3](/filings/0000006951-25-000037.md) | [8.0](/filings/0001628280-25-056742.md) | [6.3](/filings/0001628280-26-009694.md) | [6.2](/filings/0001628280-26-037227.md) | [5.4](/filings/0001628280-26-058235.md) | [7.2](/filings/0001628280-26-058235.md) | [7.2](/filings/0001628280-26-009694.md) | [6.3](/filings/0001628280-26-037227.md) | [7.0](/filings/0001628280-26-058235.md) | | Current assets | $bn | [19.1](/filings/0000006951-24-000044.md) | [19.2](/filings/0000006951-24-000012.md) | [19.3](/filings/0000006951-24-000022.md) | [20.7](/filings/0000006951-24-000032.md) | [21.2](/filings/0001628280-25-056742.md) | [20.7](/filings/0000006951-25-000011.md) | [19.7](/filings/0000006951-25-000024.md) | [19.7](/filings/0000006951-25-000037.md) | [20.9](/filings/0001628280-26-058235.md) | [21.0](/filings/0001628280-26-009694.md) | [22.6](/filings/0001628280-26-037227.md) | [25.1](/filings/0001628280-26-058235.md) | | Total assets | $bn | [30.7](/filings/0000006951-24-000044.md) | [31.5](/filings/0000006951-24-000012.md) | [31.9](/filings/0000006951-24-000022.md) | [33.6](/filings/0000006951-24-000032.md) | [34.4](/filings/0001628280-25-056742.md) | [33.3](/filings/0000006951-25-000011.md) | [33.6](/filings/0000006951-25-000024.md) | [34.2](/filings/0000006951-25-000037.md) | [36.3](/filings/0001628280-26-058235.md) | [37.6](/filings/0001628280-26-009694.md) | [40.3](/filings/0001628280-26-037227.md) | [43.5](/filings/0001628280-26-058235.md) | | Current liabilities | $bn | [7.4](/filings/0000006951-24-000044.md) | [7.1](/filings/0000006951-24-000012.md) | [6.9](/filings/0000006951-24-000022.md) | [7.2](/filings/0000006951-24-000032.md) | [8.5](/filings/0001628280-25-056742.md) | [7.7](/filings/0000006951-25-000011.md) | [8.0](/filings/0000006951-25-000024.md) | [7.9](/filings/0000006951-25-000037.md) | [8.0](/filings/0001628280-26-058235.md) | [7.8](/filings/0001628280-26-009694.md) | [9.0](/filings/0001628280-26-037227.md) | [10.4](/filings/0001628280-26-058235.md) | | Total liabilities | $bn | [14.4](/filings/0000006951-24-000044.md) | [14.1](/filings/0000006951-24-000012.md) | [13.8](/filings/0000006951-24-000022.md) | [14.8](/filings/0000006951-24-000032.md) | [15.4](/filings/0001628280-25-056742.md) | [14.7](/filings/0000006951-25-000011.md) | [14.7](/filings/0000006951-25-000024.md) | [14.7](/filings/0000006951-25-000037.md) | [15.9](/filings/0001628280-26-058235.md) | [15.9](/filings/0001628280-26-009694.md) | [16.4](/filings/0001628280-26-037227.md) | [17.9](/filings/0001628280-26-058235.md) | | Long-term debt | $bn | [5.5](/filings/0000006951-24-000044.md) | [5.5](/filings/0000006951-24-000012.md) | [5.5](/filings/0000006951-24-000022.md) | [6.2](/filings/0000006951-24-000032.md) | [5.5](/filings/0001628280-25-056742.md) | [5.5](/filings/0000006951-25-000011.md) | [5.5](/filings/0000006951-25-000024.md) | [5.5](/filings/0000006951-25-000037.md) | [6.5](/filings/0001628280-26-058235.md) | [6.5](/filings/0001628280-26-009694.md) | [5.3](/filings/0001628280-26-037227.md) | [5.2](/filings/0001628280-26-058235.md) | | Current portion of debt | $bn | [0.0](/filings/0000006951-24-000044.md) | not reported | not reported | not reported | [0.7](/filings/0001628280-25-056742.md) | [0.7](/filings/0000006951-25-000011.md) | [0.7](/filings/0000006951-25-000024.md) | [0.7](/filings/0000006951-25-000037.md) | [0.0](/filings/0001628280-26-058235.md) | not reported | [1.2](/filings/0001628280-26-037227.md) | [1.2](/filings/0001628280-26-058235.md) | | Short-term borrowings | $bn | [0.1](/filings/0000006951-24-000044.md) | [0.1](/filings/0000006951-24-000012.md) | [0.1](/filings/0000006951-24-000022.md) | [0.1](/filings/0000006951-24-000032.md) | [0.8](/filings/0001628280-25-056742.md) | [0.8](/filings/0000006951-25-000011.md) | [0.8](/filings/0000006951-25-000024.md) | [0.8](/filings/0000006951-25-000037.md) | [0.1](/filings/0001628280-26-058235.md) | [0.1](/filings/0001628280-26-009694.md) | [1.2](/filings/0001628280-26-037227.md) | [1.3](/filings/0001628280-26-058235.md) | | Shareholders' equity | $bn | [16.3](/filings/0001628280-25-056742.md) | [17.4](/filings/0000006951-25-000024.md) | [18.2](/filings/0000006951-25-000037.md) | [18.8](/filings/0000006951-25-000037.md) | [19.0](/filings/0001628280-26-058235.md) | [18.6](/filings/0001628280-26-037227.md) | [19.0](/filings/0001628280-26-058235.md) | [19.5](/filings/0001628280-26-058235.md) | [20.4](/filings/0001628280-26-058235.md) | [21.7](/filings/0001628280-26-037227.md) | [23.9](/filings/0001628280-26-058235.md) | [25.6](/filings/0001628280-26-058235.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Short-term borrowings: us-gaap:ShortTermBorrowings - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q4 FY2023 (2023-10-29) | Q1 FY2024 (2024-01-28) | Q2 FY2024 (2024-04-28) | Q3 FY2024 (2024-07-28) | Q4 FY2024 (2024-10-27) | Q1 FY2025 (2025-01-26) | Q2 FY2025 (2025-04-27) | Q3 FY2025 (2025-07-27) | Q4 FY2025 (2025-10-26) | Q1 FY2026 (2026-01-25) | Q2 FY2026 (2026-04-26) | Q3 FY2026 (2026-07-26) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [1,555 d](/filings/0001628280-25-056742.md) | [2,325](/filings/0000006951-25-000011.md) | [1,392 d](/filings/0000006951-25-000024.md) | [2,385 d](/filings/0000006951-25-000037.md) | [2,575 d](/filings/0001628280-25-056742.md) | [925](/filings/0001628280-26-009694.md) | [1,571 d](/filings/0001628280-26-037227.md) | [2,634 d](/filings/0001628280-26-058235.md) | [2,828 d](/filings/0001628280-25-056742.md) | [1,686](/filings/0001628280-26-009694.md) | [845 d](/filings/0001628280-26-037227.md) | [3,037 d](/filings/0001628280-26-058235.md) | | Capital expenditure | $m | [309 d](/filings/0001628280-25-056742.md) | [229](/filings/0000006951-25-000011.md) | [257 d](/filings/0000006951-25-000024.md) | [297 d](/filings/0000006951-25-000037.md) | [407 d](/filings/0001628280-25-056742.md) | [381](/filings/0001628280-26-009694.md) | [510 d](/filings/0001628280-26-037227.md) | [584 d](/filings/0001628280-26-058235.md) | [785 d](/filings/0001628280-25-056742.md) | [646](/filings/0001628280-26-009694.md) | [635 d](/filings/0001628280-26-037227.md) | [707 d](/filings/0001628280-26-058235.md) | | Dividends paid | $m | [268 d](/filings/0001628280-25-056742.md) | [266](/filings/0000006951-25-000011.md) | [266 d](/filings/0000006951-25-000024.md) | [331 d](/filings/0000006951-25-000037.md) | [329 d](/filings/0001628280-25-056742.md) | [326](/filings/0001628280-26-009694.md) | [325 d](/filings/0001628280-26-037227.md) | [368 d](/filings/0001628280-26-058235.md) | [365 d](/filings/0001628280-25-056742.md) | [365](/filings/0001628280-26-009694.md) | [365 d](/filings/0001628280-26-037227.md) | [420 d](/filings/0001628280-26-058235.md) | | Share repurchases | $m | [700 d](/filings/0001628280-25-056742.md) | [700](/filings/0000006951-25-000011.md) | [820 d](/filings/0000006951-25-000024.md) | [861 d](/filings/0000006951-25-000037.md) | [1,442 d](/filings/0001628280-25-056742.md) | [1,318](/filings/0001628280-26-009694.md) | [1,670 d](/filings/0001628280-26-037227.md) | [1,056 d](/filings/0001628280-26-058235.md) | [851 d](/filings/0001628280-25-056742.md) | [337](/filings/0001628280-26-009694.md) | [400 d](/filings/0001628280-26-037227.md) | [440 d](/filings/0001628280-26-058235.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividends - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q1 FY2023 (2023-01-29) | Q2 FY2023 (2023-04-30) | Q3 FY2023 (2023-07-30) | Q1 FY2024 (2024-01-28) | Q2 FY2024 (2024-04-28) | Q3 FY2024 (2024-07-28) | Q1 FY2025 (2025-01-26) | Q2 FY2025 (2025-04-27) | Q3 FY2025 (2025-07-27) | Q1 FY2026 (2026-01-25) | Q2 FY2026 (2026-04-26) | Q3 FY2026 (2026-07-26) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [849](/filings/0000006951-24-000012.md) | [847](/filings/0000006951-24-000022.md) | [843](/filings/0000006951-24-000032.md) | [837](/filings/0000006951-25-000011.md) | [836](/filings/0000006951-25-000024.md) | [833](/filings/0000006951-25-000037.md) | [819](/filings/0001628280-26-009694.md) | [812](/filings/0001628280-26-037227.md) | [802](/filings/0001628280-26-058235.md) | [799](/filings/0001628280-26-009694.md) | [799](/filings/0001628280-26-037227.md) | [800](/filings/0001628280-26-058235.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 793,597,443 at 2026-07-26, from the cover of the [10-Q filed 2026-08-20](/filings/0001628280-26-058235.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:17 ET. No prices; not investment advice.